Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02770014 · OUTCOME

Turnaround Time

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer · Source last updated 2019-11-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
Full Range
Time frame
Maximum 38 days

What was measured

The turnaround time from study registration to treatment initiation was recorded for the plasma genotyping strategy versus standard tumor genotyping. For rapid plasma genotyping, turnaround time is the time between ordering plasma genotyping and obtaining results; this time period was compared to the turnaround time of obtaining the tumor genotyping results.

Analysis population: A total of 42 participants had plasma genotyping results available (1 of the 43 enrolled participants did not have plasma genotyping).

Groups in this outcome

Participants With Plasma Genotyping

Participants who enrolled to the study and had plasma genotyping

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Participants With Plasma Genotyping42

Reported measurements

Turnaround Time: Plasma Genotyping

Analysis denominator · Participants

GroupSource count
Participants With Plasma Genotyping42
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Participants With Plasma Genotyping4Not reported111Not reported
Turnaround Time: Tumor Genotyping

Analysis denominator · Participants

GroupSource count
Participants With Plasma Genotyping35
Values in days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Participants With Plasma Genotyping20Not reported838Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        11
        value
        4
    denoms
    1. counts
      1. group Id
        OG000
        value
        42
      units
      Participants
    title
    Turnaround Time: Plasma Genotyping
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        8
        upper Limit
        38
        value
        20
    denoms
    1. counts
      1. group Id
        OG000
        value
        35
      units
      Participants
    title
    Turnaround Time: Tumor Genotyping
denoms
  1. counts
    1. group Id
      OG000
      value
      42
    units
    Participants
description
The turnaround time from study registration to treatment initiation was recorded for the plasma genotyping strategy versus standard tumor genotyping. For rapid plasma genotyping, turnaround time is the time between ordering plasma genotyping and obtaining results; this time period was compared to the turnaround time of obtaining the tumor genotyping results.
dispersion Type
Full Range
groups
  1. description
    Participants who enrolled to the study and had plasma genotyping
    id
    OG000
    title
    Participants With Plasma Genotyping
param Type
MEDIAN
population Description
A total of 42 participants had plasma genotyping results available (1 of the 43 enrolled participants did not have plasma genotyping).
reporting Status
POSTED
time Frame
Maximum 38 days
title
Turnaround Time
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice